Zoe Liang

UGenome would love to meet you in San Diego from June 1-5! #ugenome, #ugenomeai, #pharmacogenomics, #pharmacogenetics, #bioinformatics, #genetics, #dna, #research, #genomics, #medicine, #drugdiscovery, #datascience, #biostatistics, #pharma, #genomicmedicine, #sequencing, #dataanalysis, #precisionmedicine

3

✨【Flow Cytometry FAQs 1】 ✨ 🙋‍♀️ 🙋‍♂️ Q1. Is CD4 (domain 1) CD4? 🙌 A1: CD4 (domain1) is not the same as CD4, it means the first domain of CD4 protein, also known as D1 domain or Ig-likeV-type domain, so it can be used as a substitution of CD4. CD4 (cluster of differentiation 4) protein, a surface molecule of immune cells which is often used to identify and label helper T lymphocytes (CD4+T cells), consists of four domains, including an extracellular domain, a transmembrane domain and an intracellular domain. #FlowCytometry #CD4 #Protein #Immune #CellResearch 

8

2 Comments

Biocom California recently invited Sapient to contribute an article for its Lifelines Magazine edition focused on innovations in #genetherapy and #celltherapy. https://lnkd.in/gC9YfQnM While cell- and gene-based treatments are advancing rapidly, spurred by a landmark year of FDA approvals, their development is not without challenges. We discuss how #multiomics for gene and cell therapy can deliver the novel insights needed to realize the incredible therapeutic potential represented in these pipelines today: https://lnkd.in/gC9YfQnM

21

Meet Our Team at the ACS Conference! Explore a partnership that could transform your approach to drug discovery and development. Vidya Sagar Kalikivaya & Kishore V Renduchintala #ACS #DrugDiscovery #Development #CRDMO #Concept#LAXAI Life Sciences #SmallMolecule

26

In a recent Japan symposium, Labcorp leaders Catherine Ohura and Takashi Shibata discussed the history of Labcorp's central lab in Japan, its capabilities and a major lab expansion slated for 2025. Kazuya Kurachi presented on companion diagnostics (CDx) development in Japan. Labcorp’s new offerings at the lab will include flow cytometry, immunology, and anatomic pathology and histology. Learn more about our central lab capabilities in Japan: #CentralLabs #FlowCytometry

1

Our Senior Director, Protein Engineering Gregory Moore gave a presentation entitled "Modulating the immune system with CD28 costimulatory bispecific antibodies” at the Festival of Biologics in San Diego and discussed this novel approach to utilize bispecific T cell engagers for the potential treatment of patients with multiple solid tumor types. Click the link for more information on our clinical pipeline, including our leading tumor-selective costimulating bispecific antibody, XmAb808. #festivalofbiologics #proteinengineering #bispecificantibodies

61

1 Comment

Exciting news in the field of oncology! Bristol Myers Squibb's drug, #Augtyro (repotrectinib), has received FDA accelerated approval for the treatment of solid tumors with NTRK gene fusions. This groundbreaking tyrosine kinase inhibitor has demonstrated remarkable efficacy in clinical trials, significantly shrinking tumors in patients with this specific genetic feature. Augtyro's approval marks a significant milestone in the fight against cancer, offering new hope for patients with NTRK-positive solid tumors. This drug provides an additional treatment option for those who have exhausted other avenues, bringing us closer to a future where cancer is managed effectively. Kudos to the team at Bristol Myers Squibb for their tireless efforts in developing this life-changing medication! Let's continue to push the boundaries of medical innovation and make a meaningful impact in the lives of cancer patients worldwide. https://lnkd.in/eaWPKcwW #oncology #cancerresearch #precisionmedicine #medicalinnovation #immunotherapy #BristolMyersSquibb #innovation

50

1 Comment

AAV is the leader of gene therapy. But what are it's pros and cons? Let's break it down. Pros: - Current leader in vector-based gene therapy - Payload doesn't integrate into patient DNA (normally) - FDA-approved therapies on the market - Can target specific tissues for precise delivery Cons: - High cost of manufacturing - Small payload size - Good quality at scale is a challenge - Single dose administration due to high immunogenicity (for now) - Liver toxicity concerns (for now) I'm excited to see how recent advances in capsid design will fix these drawbacks. Anything else you'd add? Drop it in the comments. For content that breaks down the science of CGT: Check out #cgt_simplified “Created with BioRender.com” #genetherapy #aav #biotechnology

152

25 Comments

FDA Approves Crovalimab for the Treatment of PNH Full story in comments below

2

1 Comment

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

Denovo Biopharma LLC received an $11.8 million grant from California Institute for Regenerative Medicine (CIRM) to advance its brain cancer therapy, DB107. The grant was awarded to conduct a Phase 1/2 clinical trial at the University of California, San Francisco (UCSF) for patients with high-grade glioma and glioblastoma. Their DB107 drug, acquired from Tocagen in 2020, uses gene therapy to selectively target and destroy tumor cells. They also claim to have developed a technology to identify biomarkers that predict a patient's response to their drugs. With plans to expand its drug development process and biomarker discovery initiative over the next five years, they have raised about $180 million since its launch in 2012. They have eight drugs in its pipeline targeting cancer and mental health disorders. For more on their cutting-edge research, subscribe to sdbj.com. https://lnkd.in/gU7HkSGu

4

𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐬 𝐍𝐞𝐰 𝐃𝐚𝐭𝐚 𝐃𝐞𝐦𝐨𝐧𝐬𝐭𝐫𝐚𝐭𝐢𝐧𝐠 𝐑𝐞𝐝𝐨𝐬𝐢𝐧𝐠 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐰𝐢𝐭𝐡 𝐈𝐧 𝐕𝐢𝐯𝐨 𝐂𝐑𝐈𝐒𝐏𝐑/𝐂𝐚𝐬𝟗 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 Intellia Therapeutics, Inc. (NASDAQ: NTLA) Intellia Therapeutics, Inc., a leading gene editing company, presented new data showcasing the potential for redosing with their investigational CRISPR/Cas9 therapy, NTLA-2001, at the Peripheral Nerve Society Annual Meeting. NTLA-2001 is being developed for transthyretin (ATTR) amyloidosis. “Today’s data highlight a groundbreaking advancement for Intellia and the gene editing field. We demonstrated that redosing with CRISPR using our non-viral LNP-based delivery platform enables an additive pharmacodynamic effect on the target protein,” said John Leonard, M.D. John Leonard, Intellia’s President and CEO. While redosing is not planned for NTLA-2001, these data provide proof-of-concept for treating other diseases requiring more than one dose. NTLA-2001 is in Phase 1 trials for ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Phase 1 data showed that a one-time 55 mg dose led to a significant and durable reduction of serum TTR protein levels, which is now being evaluated in the Phase 3 MAGNITUDE trial for ATTR-CM and the upcoming Phase 3 trial for ATTRv-PN. Initial Phase 1 patients received a 0.1 mg/kg dose, resulting in a 52% median reduction in serum TTR. These patients were later redosed with 55 mg, achieving a 90% median reduction. NTLA-2001 was generally well tolerated, with safety and pharmacodynamics consistent across doses. The ability to re-dose with Intellia’s non-viral, lipid nanoparticle (LNP)-based delivery platform is a first in clinical data for CRISPR-based medicines, opening new possibilities for treating diseases requiring multiple doses for desired effects. #GeneEditing #CRISPR #ATTRAmyloidosis #GenomicMedicine #ClinicalTrials #IntelliaTherapeutics #PrecisionMedicine #LifeSciences #BiotechNews #RegenerativeMedicine

2

Our new white paper, "Rare disease diagnostics: Advancing orphan drug development through precision testing," explores how integrating multi-omics data—including genomics, epigenomics, transcriptomics, and proteomics—can offer a more comprehensive understanding of disease mechanisms. Let's discuss collaborative opportunities to accelerate breakthroughs in rare diseases. #PrecisionMedicine #RareDiseaseAdvocacy #DrugDiscovery https://lnkd.in/gPa682SF

29